Search

Your search keyword '"Metges, Jean-Phillippe"' showing total 10 results
Start Over Author "Metges, Jean-Phillippe"
10 results on '"Metges, Jean-Phillippe"'

1. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

Author

Abou-Alfa, Ghassan, Alfonso, Jorge Adeva, Aglietta, Massimo, Baron, Ari, Beg, Muhammad, Aguirre, Paula Carrasco, Chen, Eric, Cheng, Ying, Gracián, Antonio Cubillo, Dahan, Laetitia, De Braud, Filippo, Fenocchio, Elisabetta, Gbolohon, Olumide, Gillmore, Roopinder, Jary, Marine, Javle, Milind, Jiang, Yixing, Kang, Jung Hun, King, Gentry George, Kundranda, Madappa, Layos, Laura, Li, Daneng, Liang, Tingbo, Lonardi, Sara, Marathe, Omkar, Mondaca, Sebastian, Martin, Andrés J. Muñoz, Park, Joon Oh, Pazo Cid, Roberto, Fernandez, Paula Ribera, Rimassa, Lorenza, Alonso, Rosa Rodriguez, Sadeghi, Saeed, Scott, Aaron, Tan, Benjamin, Tougeron, David, Yan, Qiang, Yin, Xiaoyu, Zhao, Haitao, Harding, James J, Fan, Jia, Oh, Do-Youn, Choi, Hye Jin, Kim, Jin Won, Chang, Heung-Moon, Bao, Lequn, Sun, Hui-Chuan, Macarulla, Teresa, Xie, Feng, Metges, Jean-Phillippe, Ying, Jie'er, Bridgewater, John, Lee, Myung-Ah, Tejani, Mohamedtaki A, Chen, Emerson Y, Kim, Dong Uk, Wasan, Harpreet, Ducreux, Michel, Bao, Yuanyuan, Boyken, Lisa, Ma, Jiafang, Garfin, Phillip, and Pant, Shubham

Published
2023
Full Text
View/download PDF

2. A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer.

Author

Harding, James J, Fan, Jia, Oh, Do-Youn, Choi, Hye Jin, Kim, Jin Won, Chang, Heung-Moon, Bao, Lequn, Sun, Hui-Chuan, Macarulla, Teresa, Xie, Feng, Metges, Jean-Phillippe, Ying, Jie'er, Bridgewater, John, Lee, Myung-Ah, Tejani, Mohamedtaki A, Chen, Emerson Y, Kim, Dong Uk, Wasan, Harpreet, Ducreux, Michel, and Bao, Yuanyuan

Abstract

What is this summary about? Researchers wanted to study whether the research drug zanidatamab could help people with a type of cancer called biliary tract cancer. In some people, biliary tract cancer cells make extra copies of a gene called HER2 (also called ERBB2). This is known as being HER2-amplified. Zanidatamab is an antibody designed to destroy cancer cells that have higher-than-normal HER2 protein or gene levels. Zanidatamab is currently under research and is not yet approved for any diseases. Participants in this phase 2b clinical study had tumors that were HER2-amplified and at the advanced or metastatic stage. Participants also had cancer which had become worse after previous chemotherapy or had side effects that were too bad to continue chemotherapy. They also had to meet other requirements to be enrolled. Researchers measured the amount of HER2 protein in the tumor samples of the participants who were enrolled. There were 80 participants with tumors that were both HER2 amplified and had higher-than-normal HER2 protein amounts (considered to be 'HER2-positive'). There were 7 participants with tumors that were HER2-amplified, but had little-to-no levels of the HER2 protein (considered to be 'HER2-low'). All participants in the study were treated with zanidatamab and no other cancer treatments once every 2 weeks. What are the key takeaways? In the HER2-positive group, 33 of 80 (41%) participants had their tumors shrink by 30% or more of their original size. In half of these participants, their tumors did not grow for 13 months or longer. No participant in the HER2-low group had their tumors shrink by 30% or more. In total, 63 of 87 participants (72%) had at least one side effect believed to be related to zanidatamab treatment. Most side effects were mild or moderate in severity. No participant died from complications related to zanidatamab. Diarrhea was one of the more common side effects and was experienced by 32 of 87 participants (37%). Side effects related to receiving zanidatamab through the vein, such as chills, fever, or high blood pressure, were experienced by 29 of 87 participants (33%). What are the conclusions reported by the researchers? The results of this study support the potential for zanidatamab as a new therapy for people with HER2-positive biliary tract cancer after they had already received chemotherapy. More research is occurring to support these results. Clinical Trial Registration:NCT04466891 (HERIZON-BTC-01 study) Tweetable Abstract The HERIZON-BTC-01 study revealed zanidatamab as a potentially effective treatment for HER2-positive biliary tract cancer after standard chemotherapy fails. Read more in the lay summary by @hardingjjmd, @DrShubhamPant, and coauthors. #BiliaryTractCancer #HER2 #zanidatamab Infographic [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Data from ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Author

Klempner, Samuel J., primary, Lee, Keun-Wook, primary, Shitara, Kohei, primary, Metges, Jean-Phillippe, primary, Lonardi, Sara, primary, Ilson, David H., primary, Fazio, Nicola, primary, Kim, Tae Yong, primary, Bai, Li-Yuan, primary, Moran, Diarmuid, primary, Yang, Jianning, primary, Arozullah, Ahsan, primary, Park, Jung Wook, primary, Raizer, Jeffrey J., primary, Bang, Yung-Jue, primary, and Shah, Manish A., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Data 1 from ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Author

Klempner, Samuel J., primary, Lee, Keun-Wook, primary, Shitara, Kohei, primary, Metges, Jean-Phillippe, primary, Lonardi, Sara, primary, Ilson, David H., primary, Fazio, Nicola, primary, Kim, Tae Yong, primary, Bai, Li-Yuan, primary, Moran, Diarmuid, primary, Yang, Jianning, primary, Arozullah, Ahsan, primary, Park, Jung Wook, primary, Raizer, Jeffrey J., primary, Bang, Yung-Jue, primary, and Shah, Manish A., primary

Published
2023
Full Text
View/download PDF

5. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Author

Klempner, Samuel J., primary, Lee, Keun-Wook, additional, Shitara, Kohei, additional, Metges, Jean-Phillippe, additional, Lonardi, Sara, additional, Ilson, David H., additional, Fazio, Nicola, additional, Kim, Tae Yong, additional, Bai, Li-Yuan, additional, Moran, Diarmuid, additional, Yang, Jianning, additional, Arozullah, Ahsan, additional, Park, Jung Wook, additional, Raizer, Jeffrey J., additional, Bang, Yung-Jue, additional, and Shah, Manish A., additional

Published
2023
Full Text
View/download PDF

6. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

Author

Harding, James J, primary, Fan, Jia, additional, Oh, Do-Youn, additional, Choi, Hye Jin, additional, Kim, Jin Won, additional, Chang, Heung-Moon, additional, Bao, Lequn, additional, Sun, Hui-Chuan, additional, Macarulla, Teresa, additional, Xie, Feng, additional, Metges, Jean-Phillippe, additional, Ying, Jie'er, additional, Bridgewater, John, additional, Lee, Myung-Ah, additional, Tejani, Mohamedtaki A, additional, Chen, Emerson Y, additional, Kim, Dong Uk, additional, Wasan, Harpreet, additional, Ducreux, Michel, additional, Bao, Yuanyuan, additional, Boyken, Lisa, additional, Ma, Jiafang, additional, Garfin, Phillip, additional, Pant, Shubham, additional, Abou-Alfa, Ghassan, additional, Alfonso, Jorge Adeva, additional, Aglietta, Massimo, additional, Baron, Ari, additional, Beg, Muhammad, additional, Aguirre, Paula Carrasco, additional, Chen, Eric, additional, Cheng, Ying, additional, Gracián, Antonio Cubillo, additional, Dahan, Laetitia, additional, De Braud, Filippo, additional, Fenocchio, Elisabetta, additional, Gbolohon, Olumide, additional, Gillmore, Roopinder, additional, Jary, Marine, additional, Javle, Milind, additional, Jiang, Yixing, additional, Kang, Jung Hun, additional, King, Gentry George, additional, Kundranda, Madappa, additional, Layos, Laura, additional, Li, Daneng, additional, Liang, Tingbo, additional, Lonardi, Sara, additional, Marathe, Omkar, additional, Mondaca, Sebastian, additional, Martin, Andrés J. Muñoz, additional, Park, Joon Oh, additional, Pazo Cid, Roberto, additional, Fernandez, Paula Ribera, additional, Rimassa, Lorenza, additional, Alonso, Rosa Rodriguez, additional, Sadeghi, Saeed, additional, Scott, Aaron, additional, Tan, Benjamin, additional, Tougeron, David, additional, Yan, Qiang, additional, Yin, Xiaoyu, additional, and Zhao, Haitao, additional

Published
2023
Full Text
View/download PDF

7. Supplementary Data from Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Author

Shah, Manish A., primary, Shitara, Kohei, primary, Lordick, Florian, primary, Bang, Yung-Jue, primary, Tebbutt, Niall C., primary, Metges, Jean-Phillippe, primary, Muro, Kei, primary, Lee, Keun-Wook, primary, Shen, Lin, primary, Tjulandin, Sergei, primary, Hays, John L., primary, Starling, Naureen, primary, Xu, Rui-Hua, primary, Sturtz, Keren, primary, Fontaine, Marilyn, primary, Oh, Cindy, primary, Brooks, Emily M., primary, Xu, Bo, primary, Li, Wei, primary, Li, Chiang J., primary, Borodyansky, Laura, primary, and Van Cutsem, Eric, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table from Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Author

Shah, Manish A., primary, Shitara, Kohei, primary, Lordick, Florian, primary, Bang, Yung-Jue, primary, Tebbutt, Niall C., primary, Metges, Jean-Phillippe, primary, Muro, Kei, primary, Lee, Keun-Wook, primary, Shen, Lin, primary, Tjulandin, Sergei, primary, Hays, John L., primary, Starling, Naureen, primary, Xu, Rui-Hua, primary, Sturtz, Keren, primary, Fontaine, Marilyn, primary, Oh, Cindy, primary, Brooks, Emily M., primary, Xu, Bo, primary, Li, Wei, primary, Li, Chiang J., primary, Borodyansky, Laura, primary, and Van Cutsem, Eric, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure from Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Author

Shah, Manish A., primary, Shitara, Kohei, primary, Lordick, Florian, primary, Bang, Yung-Jue, primary, Tebbutt, Niall C., primary, Metges, Jean-Phillippe, primary, Muro, Kei, primary, Lee, Keun-Wook, primary, Shen, Lin, primary, Tjulandin, Sergei, primary, Hays, John L., primary, Starling, Naureen, primary, Xu, Rui-Hua, primary, Sturtz, Keren, primary, Fontaine, Marilyn, primary, Oh, Cindy, primary, Brooks, Emily M., primary, Xu, Bo, primary, Li, Wei, primary, Li, Chiang J., primary, Borodyansky, Laura, primary, and Van Cutsem, Eric, primary

Published
2023
Full Text
View/download PDF

10. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Author

Shah, Manish A., primary, Shitara, Kohei, additional, Lordick, Florian, additional, Bang, Yung-Jue, additional, Tebbutt, Niall C., additional, Metges, Jean-Phillippe, additional, Muro, Kei, additional, Lee, Keun-Wook, additional, Shen, Lin, additional, Tjulandin, Sergei, additional, Hays, John L., additional, Starling, Naureen, additional, Xu, Rui-Hua, additional, Sturtz, Keren, additional, Fontaine, Marilyn, additional, Oh, Cindy, additional, Brooks, Emily M., additional, Xu, Bo, additional, Li, Wei, additional, Li, Chiang J., additional, Borodyansky, Laura, additional, and Van Cutsem, Eric, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results